Product Description
Lacripep, which is derived from the Lacritin protein, is a first-in-class topical therapy that preserves all of Lacritin's bioactivity. (Sourced from: https://tearsolutions.com)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TearSolutions
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Corneal Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06854393 |
WRNMMC-2024-0470 | P2 |
Recruiting |
Corneal Injuries |
2027-06-01 |
12% |
2025-07-04 |
Primary Endpoints|Start Date|Treatments|Trial Status |